It is administered subcutaneously and is designed to help manage bleeding in individuals with hemophilia A (congenital factor VIII deficiency) and FVIII inhibitors and in individuals with hemophilia B (congenital factor IX deficiency) and FIX inhibitors [27]. The gene discussed is F9; the disease is hemophilia B.